A B S T R A C T A rapid and relatively simple method for measurement of inorganic pyrophosphate (PPi) in biological samples has been described. The mean ±SEM of plasma samples from 94 normal subjects was 1.8± 0.06 AM, giving a normal range (99% confidence limits) of 0.16 -3.40 iimo/liter. Analysis of 17 plasma samples in duplicate showed a standard deviation of 0.18, giving a 99% probability that a single determination of plasma PPi would be ±0.68 4M of the true value.
INTRODUCTION
It has become evident in recent years that further understanding of the pseudogout syndrome (1-3) (calcium pyrophosphate dihydrate crystal deposition disease) requires a better understanding of the metabolism of inorganic pyrophosphate (PPi).' Recently, Russell and vacuum desiccator. All centrifugation was performed at 4VC in a Sorvall RC-2 Centrifuge (Ivan Sorvall, Inc., Newtown, Conn.) unless otherwise specified.
Blood or other fluid was drawn into a plastic syringe containing a tracer amount of [8'P] inorganic pyrophosphate ('P'Pi) of high specific activity (770-6200 pCi/Amol), ( New England Nuclear, Boston, Mass.) and sodium heparin (50 ,.l/10-ml sample as Liquemin Sodium "10," Organon Inc., West Orange, N. J.), and placed directly in ice. The entire procedure was then carried out in ice except where otherwise specified. It is important that venipuncture or other procedure used to obtain the specimen be performed as atraumatically as possible. Serum contains two to threefold as much PPi as does plasma prepared from the same blood. The increased PPi concentration of serum is due to its release by platelets. The identification of PPi in platelets and its release upon thrombin stimulation are described elsewhere (10) . Platelet-poor plasma was prepared by centrifugation at 1110 g for 15 min; the supernate was then centrifuged at 49,500 g for 10 min, decanted, and centrifuged again at 49,500 g for 20 min.
Analysis for PPi
The procedure as used for plasma samples was as follows:
Initial 'P3"Pi concentration. Two 100-,l aliquots of sample were counted in 10 ml of 0.5 N HCl in water using Cerenkov emission and a Packard Tri-Carb Liquid Scintillation Counter, Model 3320 (Packard Instrument Co., Inc., Downers Grove, Ill.). The efficiency of this technique approximated 50%.
Deproteinization. 0.6 ml of 80% (wt/vol) trichloroacetic acid was added to 5 ml of sample in a 15-ml Nalgene conical tube (Nalgene Piping Systems Div., Nagle/Sybron Corp., Rochester, N. Y.), and mixed in a vortex until homogeneous; after centrifugation at 28,000 g for 10 min, 3 .5 ml of supernate was removed with a plastic pipette and transferred to a 15-ml plastic centrifuge tube.
Removal of inorganic orthophosphate (Pi) and residual protein. This was done by a modification of the method of Sugino and Miyoshi (11): 0.8 ml of a solution of four parts 1 N perchloric acid and one part 0.08 M ammonium molybdate were added, and after thorough mixing, 0.4 ml of 0.1 M triethylamine hydrochloride, pH 5.0. The final acid normality was 0.5. The resultant cloudy green precipitate was allowed to form for 5 min. After centrifugation at 28,000 g for 10 min, the clear supernate was poured into another tube and centrifuged again at 40,000 g for 15 min. (It is important that no precipitate be carried over into the next step.) 4 ml of supernate was transferred to a 50-ml glass-stoppered centrifuge tube with a blowout pipette.
Extraction of residual Pi and concentration of sample by removal of water. 1 ml of 1 N HCl was added to increase efficiency of isobutanol extraction, and to avoid the development of phosphomolybdenum blue. Then 30 ml of cold isobutanol was added, the tube inverted by hand repeatedly and rapidly for 30 s, after which the phases were separated by centrifugation at 425 g for 10 min. After removal of the isobutanol phase by suction, the sample was transferred to a 15-ml conical tube with a Pasteur pipette, 0.2 ml of 1 M Tris-HCl buffer, pH 7.2, was added, and the pH adjusted to 7.2±0.2 with 25-30 Al of 40% (wt/vol) KOH; 3-5 ml of isobutanol was then added to further reduce the volume to 0.4-0.5 ml. The organic phase was removed, and 1 ml of benzene was added under hood precautions. This solution was thoroughly mixed for 30 s and centrifuged at 1500 g for 10 min in an International Centrifuge, model Colorimetric measurement of Pi. The method used was adapted from that described by Chen, Toribara, and Warner (12) . 10 ul of 6.5% (wt/vol) ammonium molybdate was first added and, during continuous mixing with a Vortex Genie (Vortex Mixers, Scientific Industries, Inc., Queens Village, N. Y.), 50 p1. of 6.5% ascorbic acid was added slowly. After incubation at 450C for 50 min all samples were again placed in ice and OD800 was measured in a Beckman DU spectrophotometer (Beckman-Instruments, Fullerton, Calif.), equipped with a Gilford model 222 absorbance indicator (Gilford Instrument Laboratories, Oberlin, Ohio), and automatic cuvette positioner model 210; 600 pl cuvettes, 1-cm light path, centered to read 100-200 pul were used.
Standard Pi solutions and a reagent blank were carried through the procedure.
Spontaneous hydrolysis in control sample during colorimetric step. An additional 100 pl of the control sample was carried through the colorimetric reaction, with water substituted for ascorbic acid. Triethylamine precipitation of phosphomolybdate was carried out as described above and the percent hydrolysis calculated.
Calculations. The PPi concentration in the original sample was calculated by isotopic dilution after correction of the AOD for possible incomplete enzyme action and for spontaneous hydrolysis in the control. Color development has been reported as a result of the interaction of PPi and ammonium molybdate under certain conditions (13, 14) . Therefore, standard solutions of Pi and of PPi were prepared in 10 mM Tris-Cl buffer (pH 7.2) and in simulated deproteinized plasma that had been carried through the preparative procedures described above. The final concentrations of both Pi and PPi was 5 ,uM. 100 ml of the simulated plasma contained 14 meq of NaCl, 8 mg of MgCl2 6 H20, 13.4 mg K2HP04, and 2.7 mg NaH2PO4-H20. Additional samples were prepared containing both Pi and PPi, each at final concentrations of 5 gM. After incubation, the solutions were scanned from 320 to 900 in a Carey model 14 recording spectrophotometer (Applied Physics Corp., Monrovia, Calif.); the light source was changed to tungsten at 800 nm.
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Specificity of yeast inorganic pyrophosphatase (PPiase)
Although this enzyme is highly specific, Schlesinger and Coon (15) , and Kunitz (16) have described activity against ATP using zinc as a cofactor. To determine possible activity against nucleotides in our system, 'P'Pi was di- 
Recovery experiments and duplicate analyses
PPi was added to plasma and to simulated plasma to final concentrations of 0-5.0 uM. Duplicate analyses were performed on 17 consecutive plasma samples from normal subjects or patients with nonsystemic forms of arthritis, and on 18 consecutive synovial fluid samples obtained from the knees of patients with various types of arthritis.
Application of the method to urine
Urinary Pi levels were determined by the method of Fiske and SubbaRow (17) in seven sequential samples from a healthy 34-yr-old Caucasian man during varying degrees of hydration. Urine osmolality was obtained by measuring freezing point depression (Advanced Instruments, Inc., Needham Heights, Mass.). If necessary, the samples were diluted to reduce the Pi concentration below 1.5 mM, and the PPi determined in 5-ml samples as described above.
Plasma PPi levels in normal subjects and in patients with pseudogout, osteoarthritis, acromegaly, and uremia Platelet-poor plasma was prepared from blood obtained from the antecubital vein of 94 normal subjects of both I sexes ranging in age from newborn (cord blood) to 87 yr. PPi was measured as described above and Pi was measured by the method of Fiske and SubbaRow (17) . Pi and PPi were also determined in 33 patients with definite pseudogout as diagnosed by our previously published criteria (3); in 30 patients with osteoarthritis of the knee or hip, or with the primary generalized form of this disease; and in 12 patients with definite rheumatoid arthritis by American Rheumatism Association criteria (18) . All patients were attending the outpatient clinic or were hospitalized at the University of Chicago. Five samples from three patients with uremia, and four samples from three patients with active acromegaly were also analyzed.
RESULTS
Analysis for PPi. The method was reliable and relatively easy to perform. A single technician can analyze 30 samples a week for both Pi and PPi. With experience, the procedure was shortened by elimination of the checks for completeness of enzymatic hydrolysis and for the percent of PPi hydrolyzed by acid in the buffer portion during the colorimetric procedure; repeated determinations showed that these figures were virtually constant at 98-100% and 9-11%, respectively.
Conditions for colorimetric assay. The effect upon the ODmoo of reduced phosphomolybdate of varying final concentrations of ammonium molybdate at different acid normalities is shown in Fig. 1 . These effects were determined as molybdate was used to remove the endogenous Pi in the original sample. The original Chen colorimetric method for Pi uses 2.0 molybdate and 0.6 N acid concentrations (12) . We added sufficient molybdate for the colorimetric reaction to achieve a final concentration of 1.2 mM, so that even if the initial sample contained only 0.5 mM Pi, the final molybdate concentration would be no greater than 7.0 mM.2 Thus the OD at a final acid concentration of 0.86 N was proportional to the Pi present as reduced phosphomolybdate in the sample.
The uM absorbance for Pi using these conditions was 0.02, or 0.04 OD/i'M PPi in the final solution. This color was developed maximally in 45 min and was stable for at least 24 h. In practice, the tubes were placed in ice after incubation and read promptly in order to prevent more than 11% hydrolysis of the PPi in the buffer portion. IjC104 was substituted for H2SO4 used by Chen et al. (12) under the conditions described (Table I ). There was 8% hydrolysis of PPi in buffer, and in simulated plasma 22.5% of the added PPi was hydrolyzed. The only absorbance peak was 800 nm; no peak was seen at 575 nm as described for the PPi-molybdate chromophore (13) .
Specificity of yeast inorganic pyrophosphatase. The hydrolysis of bovine ATP under the conditions described above was not measurable (Fig. 2) . Even with the more sensitive radiochemical method (19) Fig. 3B . Application of the method to urine and plasma. Urinary Pi and PPi concentrations are given in Table III , together with the osmolality of each sample. Proportionality was found over a wide range of concentration. The PPi concentrations found in plasma samples from 94 normal subjects ranging in age from newborn (cord tion; the mean value of the lower curve was 1.9 /AM (Fig. 6A) . Probit analysis suggested a bimodal distribution of values (Fig. 5) . The mean PPi level in samples from osteoarthritis patients was 2.62±0.12 FM, also differing significantly from the normal mean (P < 0.01), but not from the mean of the pseudogout patients (P = NS) (Fig. 6B) . The mean values of plasma PPi in samples from patients with rheumatoid arthritis, acromegaly, and uremia was 1.85±0.14 iAM, 5.9±2.2 /AM, and 3.4± 1.14 .AM, respectively. The distribution of probit points in rheumatoid arthritis closely approximated the normal distribution (Fig. 5) . Plasma Pi levels in the normal series (n = 90) were 1.03±0.02 mM. Pi values in samples from osteoarthritis patients (n = 29) showed a mean of 1.03±0.03, from pseudogout patients (n = 33) 0.96±0.04 mM, from rheumatoid arthritis patients (n = 12) 1.08±0.04 mM, from uremic subjects (n= 5) 3.39±0.98 mM, and from acromegalic patients (n = 4) 1 Relatively little is known of PPi metabolism. Application of the method described in this paper and of the other procedures mentioned here should greatly expand our knowledge of the biological significance of this important metabolite.
The PPi levels in rheumatoid arthritis plasma samples showed a mean nearly identical to that found in normal controls (Fig. 5) , whereas the mean PPi values in both osteoarthritis and pseudogout were significantly elevated. The increase in plasma PPi in some samples from patients with osteoarthritis and pseudogout was unexpected and cannot be readily explained. Many of these patients were elderly, but age per se does not seem to be a factor, as no significant difference in plasma PPi was noted in the aged normal subjects as compared to their younger counterparts. The synovial fluid PPi levels are often elevated in patients with pseudogout (4) (5) (6) and with osteoarthritis (6) .' It is conceivable that diffusion from the joint into the systemic circulation could account for the observed increase. Indeed, measurement of the PPi concentrations in paired femoral arterial and femoral venous blood samples show a mean PPi gradient of 25%.' The samples analyzed are relatively few, and until something is known of the origin of plasma PPi and the factors influencing its turnover, we prefer to regard the findings reported here as tentative. In any event, the highest values found are far from those representing the apparent solubility of PPi in plasma equilibrated with crystalline calcium pyrophosphate dihydrate (5) . 8 Elevated levels of plasma PPi in uremic subjects have been reported previously by Russell, Bisaz, and Fleisch (22) . Only one of five samples in our series was above the normal range, although the mean of the remaining four was 2.8 /AM. Russell and coworkers speculate that such levels may be explained simply by a decreased glomerular filtration rate leading to retention of both Pi and PPi, or to increased inhibition by Pi of enzymatic hydrolysis of PPi by the kidney. Growth hormone is thought to increase plasma Pi by increased renal tubular resorption of phosphate (23) . The association of joint disease closely resembling osteoarthritis with active acromegaly suggests that the elevation of PPi in these conditions may share a common pathway. Acromegaly has been reported in association with pseudogout (24), but no systemic search for calcium pyrophosphate crystal deposition has been made in acromegalic patients. 
